Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ilepatril

Known as: (4S,7S,12BR)-7-((2S)-2-(Acetylsulfanyl)-3-Methylbutanamido)-6-Oxo-1,2,3,4,6,7,8,12b-Octahydropyrido(2,1-A)(2)Benzazepine-4-Carboxylic Acid 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

AVE 7688

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Cardiorenal protection in experimental hypertension with renal failure: comparison between vasopeptidase inhibition and angiotensin receptor blockade
Abstract Objective: The aim of the present study was to compare the preventive impact of treatment with a vasopeptidase inhibitor… Expand
Highly Cited
2012
Highly Cited
2012
Early loss of innervation of cornea epithelium in streptozotocin-induced type 1 diabetic rats: improvement with ilepatril treatment.
PURPOSE Cornea confocal microscopy is emerging as a clinical tool to evaluate the development and progression of diabetic… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2012
2012
Effect of inhibition of angiotensin converting enzyme and/or neutral endopeptidase on vascular and neural complications in high fat fed/low dose streptozotocin-diabetic rats.
Treating high fat fed/low dose streptozotocin-diabetic rats; model of type 2 diabetes, with ilepatril (vasopeptidase inhibitor… Expand
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
2012
2012
Effect of Inhibition of Angiotensin-Converting Enzyme and/or Neutral Endopeptidase on Neuropathy in High-Fat-Fed C57Bl/6J Mice
We have demonstrated that treating diet-induced obese (DIO) mice with the vasopeptidase inhibitor ilepatril improved neural… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 4
2012
2012
Assessing diabetic neuropathy using corneal confocal microscopy.
  • N. Efron
  • Investigative ophthalmology & visual science
  • 2012
    • Corpus ID: 11779516
N europathy is a frequent complication of diabetes and is a major cause of morbidity and mortality, potentially affecting distal… Expand
2011
2011
Effect of treatment of high fat fed/low dose streptozotocin-diabetic rats with Ilepatril on vascular and neural complications.
We have previously shown that treating streptozotocin-induced diabetic rats, an animal model of type 1 diabetes, with Ilepatril… Expand
2011
2011
Vasopeptidase inhibitor ilepatril (AVE7688) prevents obesity- and diabetes-induced neuropathy in C57Bl/6J mice
Previously we demonstrated that inhibition of neutral endopeptidase (NEP), a protease that degrades vaso- and neuro-active… Expand
2011
2011
Role of the effect of inhibition of neutral endopeptidase on vascular and neural complications in streptozotocin-induced diabetic rats.
We have previously shown that treating streptozotocin-induced diabetic rats, an animal model of type 1 diabetes, with Ilepatril… Expand
Review
2008
Review
2008
Ilepatril (AVE-7688), a vasopeptidase inhibitor for the treatment of hypertension.
  • R. Tabrizchi
  • Current opinion in investigational drugs
  • 2008
    • Corpus ID: 11705565
sanofi-aventis (formerly Aventis Pharma AG) is developing ilepatril (AVE-7688), a dual angiotensin-converting enzyme and neutral… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE